Low-Dose Naltrexone-Induced Remission in Hailey–Hailey Disease Maintained in Remission with Topical Combination of Ketamine and Diphenhydramine

Abstract
Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey–Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication. With lack of safety data on long-term administration of LDN, we explored the utility of a topical diphenhydramine/ketamine (DK) cream in maintaining the remission achieved with LDN. A 42-year-old male with treatment-refractory HHD remitted with 5 mg naltrexone/day but relapsed on stopping the drug. Symptoms abated after restarting LDN. The impact of regular twice-a-day application of a specially formulated DK cream containing diphenhydramine (2% w/w) and ketamine (1% w/w) over the affected areas on maintenance of remission was explored till the next relapse. Our approach enabled dose reduction of naltrexone to 3 mg/day without loss of treatment benefit. After 3-month overlap of naltrexone and DK cream, withdrawal of naltrexone maintained remission with only the topical regime with no adverse effects till 4 months of follow-up. The use of topical agents with anti-inflammatory, antipruritic, antinociceptive, and naltrexone-mimicking properties merits exploration as an option to provide short but significant period of naltrexone-free maintenance of remission to patients with HHD.

Keywords: Benign familial pemphigus, diphenhydramine, Hailey–Hailey disease, ketamine, low-dose opioid, naltrexone

Introduction
Hailey–Hailey disease (HHD) arises from a defect in keratinocyte adhesion possibly secondary to a primary defect in a calcium pump protein, ATP2C1.[1,2] The itchy, painful, and malodorous flexural lesions significantly impair patients’ quality of life. Only temporary symptom alleviation has been reported with tried drugs.[1,2] Recent discovery of low-dose naltrexone (LDN) as a novel agent for HHD has sparked interest. The documented efficacy of LDN for HHD is offset by the immediate postcessation relapse,[2‑5] prompting exploration of therapeutic options to maintain the remission achieved. We compounded a topical diphenhydramine/ketamine (DK) combination cream with anti-inflammatory, antipruritic, antinociceptive, and naltrexone-like effects. Our encouraging results merit exploration of this approach in properly designed studies to provide maintenance of remission to patients with HHD during naltrexone-free period(s).

Case Details
A 42-year-old male with biopsy-confirmed HHD of 8 years and a strong family history presented with erythematous, macerated, and eroded plaques over the groins [Figure 1a and b]. His medical history included topical and systemic steroids, antibiotics, dapsone, cyclosporine, and methotrexate; all had to be stopped owing to suboptimal response, relapse on cessation, and/or sustenance of drug-induced hepatic/renal dysfunction. The patient refused ablative therapies and botulinum toxin as treatment options. Oral naltrexone was initiated at 5 mg/day once at night after discontinuing other medications. One 50 mg naltrexone tablet was dissolved in 50 mL of distilled water in an amber-colored plastic container and left over for 2 h. The insoluble excipients that gave a cloudy appearance were filtered off to obtain a clear, relatively excipient-free solution containing 1 mg/mL of naltrexone.

Address for correspondence:
Dr. Ankur Talwar,
Department of Dermatology and STD, HIMS Institute, Safedabad, Uttar Pradesh, India.
E-mail: docankurtalwar@gmail.com

For reprints contact: reprints@medknow.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Sonthalia S, Agrawal M, Talwar A, Goldust M. Low-dose naltrexone-induced remission in Hailey–Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine. Indian Dermatol Online J 2019;10:567-70.

Received: November, 2018. Accepted: January, 2019.
Confirmation of the expected drug concentration done by testing 1 mL solution with high-performance liquid chromatography-electrochemical detection revealed 0.99 mg/mL (almost 1 mg/mL). About 5 mL of the clear solution was administered to the patient after mixing with fruit juice to mask the bitter taste. The filtered stock solution was given to the patient to store in refrigerator at 4°C; stability was maintained for 60 days in contrast to less than 30 days at 25°C.[6]

Healing started within 2 weeks, with 90% improvement in lesions [Figure 1c and d], symptoms, and quality of life by 1 month. Hemogram and metabolic panel after 1 month of therapy revealed no abnormality over the baseline values. LDN (5 mg/day) was continued for 12 weeks, but new erosions developed within 2 weeks of cessation leading to recommencement of LDN (5 mg/day). We considered preparing a safe, corticosteroid-free topical formulation with potent anti-inflammatory, antipruritic, and naltrexone-mimicking properties. A nonirritant and stable DK cream containing diphenhydramine (2% w/w) and ketamine (1% w/w) specially compounded using pluronic lecithin organogel (PLO) as the vehicle base was given for regular twice-a-day application over the groins after a negative patch test. The application amount was around 2–2.5 mL on each side, with maximum 10 mL/day. The cream was started in the third week of having restarted the patient on 5 mg/day oral LDN. Three weeks later, LDN was tapered to 3 mg/day while DK cream was continued; this combination was continued for 3 months with sustained remission and no adverse effects (AEs).

Thereafter, naltrexone was withdrawn while continuing DK cream. Surprisingly, the patient remained in remission for at least 4 more months requiring application of mometasone–mupirocin cream only on two occasions. On both occasions, swab from the mild discharge was negative for any bacterial growth on culture. However, after 4 months, LDN (3 mg/day) had to be restarted to control a gradually occurring mild but definite relapse. Patient’s Dermatology Quality of Life Index (DLQI) improved remarkably from 22 (before LDN) to 2 (after 7 months, till the continuation of LDN)) with mild increase to 4 during the 4-month naltrexone-free period. Figure 2 schematically summarizes the patient’s clinical course with details of changes made in the therapeutic protocol and response.

Discussion

Naltrexone, an inhibitor of µ-opioid receptors, is approved by the United States Food and Drug Administration for opioid addiction management, typically given at a dose of 50–100 mg daily. In addition to its action on opioid receptors leading to wound healing, it is also a toll like receptor 4 (TLR4) antagonist which is responsible for correcting the calcium homeostasis.[7,8]

In the handful of studies conducted on use of LDN in HHD, relapse after cessation occurred in all.[2–5] Our current naiveté regarding long-term AEIs of LDN prompted our quest for a maintenance agent. The topical DK regimen allowed naltrexone dose reduction and provided at least a 4-month LDN-free remission to the patient. Topical diphenhydramine exerts potent antipruritic, anti-inflammatory, antibacterial and anesthetic effects and reinforces the epidermal barrier function.[9–11] Ketamine, a high-affinity antagonist of the glutamate
N-methyl-D-aspartate receptor, exerts potent antinociceptive and anesthetic properties by various mechanisms especially stimulation of the γ-aminobutyric acid_\_ receptors,\(^{12,13}\) suppresses the release of proinflammatory cytokines through TLR4/2 inhibition, and mimics the biological effects of LDN\(^{13,14}\) Table 1 summarizes the biological effects of these agents.

Topical ketamine has been used with lidocaine and amitriptyline for various neuropathic pain-related and itchy disorders with well-established safety. Furthermore, blood levels of ketamine in patients on topical ketamine have been reported as below detection level in multiple studies.\(^{13}\) Currently, a safe amount of topical ketamine cannot be precisely specified owing to several factors determining systemic absorption such as concentration, vehicle (hydrogel > PLO > oil-in-water base), surface area covered, occlusion, and thinness of the skin. In a double-blind randomized controlled trial that compared the efficacy and safety of topical preparations of 2% amitriptyline, 1% ketamine, their combination, and

| Site of action | Biological effect |
|----------------|-------------------|
| Diphenhydramine | Inhibition of H1r resulting in direct cutaneous antipruritic effect |
| H1/2r (type 1>>type 2) | Improvement of epidermal barrier by opposing mast cell-derived histamine |
| H1/2r | Induction of expression of these epidermal differentiation-related proteins resulting in enhanced epidermal differentiation, leading to more robust corneocytes |
| Location - epidermal | Overall impact - improved epidermal barrier repair |
| H1/2r | Increased synthesis of these enzymes leading to enhanced epidermal lipid synthesis |
| Location - dermal mast cells | Increased synthesis resulting in better lipid secretion by enhanced deposition of lamellar body contents at the stratum granulosum-corneum interface |
| Involucrin, loricrin, and filaggrin | Surfactant effect leading to altered permeability and function of bacterial membrane - bacteriostatic effect |
| Epidermal HMG CoA reductase, serine palmitoyl transferase, FA2H, and the elongation enzyme (ELOVL4) | Inhibition of the release of L-glutamate, which is present at a majority of excitatory synapses |
| Epidermal-specific, transmembrane transporter, ABCA12 (that delivers glucosylceramides into nascent lamellar bodies) | Stimulation of the GABA_\_ receptor |
| Cell membranes of certain bacteria including S. aureus and S. epidermidis | *Induction of blockade of the channel |
| Ketamine | **Activation of nNO synthase |
| ^NMDA receptor | Delay in desensitization and improvement in resensitization of μ receptors |
| GABA_\_ receptor | ***Inhibition and reduction in the expression of TLR4 and 2 |
| HCN1 pacemaker channels | Inhibition of the upregulation of CD18 and CD62L (in activated human neutrophils), and CD11b and CD16 (which bind to complement- or immunoglobulin-opsonized particles) resulting in reduction of leukocyte adherence and arrest of complement/immunoglobulin-mediated inflammatory cascade |
| nNO synthase | Suppression of activation of NF-kB and AP-1 resulting in inhibition of TNF-α gene expression |
| μ and κ opioid receptors - simulation of naltrexone effect | |
| TLR4 - simulation of naltrexone effect | |
| TLR2 | |
| Cell adhesion molecules - CD11b, CD16, CD18, CD62L | |
| NF-kB and AP-1 | |

\(^{1}\)H1/2r=Histamine type 1/2 receptors; FA2H=Fatty acid 2-hydrolyase; ELOVL4=Elongation of very long-chain fatty acid-4; NMDA=Glutamate N-methyl-D-aspartate receptor; GABA_\_=γ-aminobutyric acid_\_; nNO=Neuronal nitric oxide; TLR=Toll-like Receptor; NF-kB=Nuclear factor-kappa B; AP-1=Activator protein; ^NMDA receptors are widely present in the peripheral nervous system; all sensorimotor axons bear them; cutaneous inflammation upregulates the NMDA receptors present over the peripheral neuronal axons; *Blockade of HCN1 channels is probably the major mechanism that imparts ketamine its potent anesthetic property; **Activation of nNO synthase also contributes to the anesthetic effect; activation of nNO synthase by ketamine stimulates the L-arginine/NO/cyclic GMP pathway to induce peripheral antinociceptive effects, ***In HHD, bacterial infection and inflammation potentiate acantholysis necessitating antibiotic and steroid applications. Gram-negative bacteria-derived lipopolysaccharide (LPS) and Gram-positive bacteria-derived lipoteichoic acid (LTA) act as specific ligands for TLR4 and TLR2 signaling pathways, respectively, induce TLR4 activation that transactivates the production of proinflammatory cytokines. By inhibiting and reducing the expression of TLR4, ketamine significantly reduces the release of proinflammatory cytokines such as IL-6, IL-1, and TNF-α.
placebo – 4 mL of each cream was given for thrice-a-day application (12 mL/day) in patients with mixed neuropathic pain for 3 weeks. Of the 45 patients who received ketamine 1% or ketamine 1%–amitriptyline 2% combination cream, blood levels of ketamine at 3 weeks were detectable only in three patients (20–33 ng/mL) with none sustaining any systemic AEs.\textsuperscript{[13,15]} The daily application amount in our report was lesser, and with the existant evidence of minimal to nil blood levels of ketamine on topical application of its 1% cream that too to a localized area, the likelihood of any significant blood absorption and systemic AEs is highly unlikely with topical ketamine 1%. In fact, reported clinically significant side effects are rare despite using higher concentrations of topical ketamine (5%–20%) with measured plasma levels of ketamine and norketamine (its metabolite) below the threshold of detection in various studies.\textsuperscript{[15]} Akin to any topical ingredient, ketamine may have some potential for contact sensitization; however, it has not been reported in the studies conducted on topical ketamine till date. We still recommend that the DK cream preferably be used after patch testing by the patient.

In HHD, physical triggers and secondary bacterial infection induce and sustain acantholysis and inflammatory cascade. The antipruritic, antinociceptive, anesthetic, and anti-inflammatory effects of both the agents plus the bacteriostatic effect of diphenhydramine and naltrexone-mimicking effects of ketamine make DK cream an efficacious and safe agent for maintaining the therapeutic effect of LDN topically. We propose that DK cream may prove useful in HHD as an adjuvant to intermittent LDN treatment and for providing sustained maintenance of remission and low DLQI for at least few months even after discontinuation of LDN.

**Conclusion**

This case not only adds on to the existing anecdotal evidence favoring the role of LDN in the management of HHD but also offers a topical regimen of diphenhydramine and ketamine to maintain the remission. Although the concentration of ketamine and the surface area of application were low, inability to measure blood levels of ketamine constitutes a major limitation. We recommend systematic exploration of this combination in studies with more patients with HHD.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Arora H, Bray FN, Cervantes J, Falto Aizpurua LA. Management of familial benign chronic pemphigus. Clin Cosmet Investig Dermatol 2016;9:281-90.
2. Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey-Hailey disease with low-dose naltrexone. JAMA Dermatol 2017;153:1018-20.
3. Cao S, Lilly E, Chen ST. Variable response to naltrexone in patients with Hailey-Hailey disease. JAMA Dermatol 2018;154:362-3.
4. Campbell V, McGrath C, Corry A. Low dose naltrexone: A novel treatment for Hailey-Hailey disease. Br J Dermatol 2017;178:1196-8.
5. Ibrahim O, Hogan, SR, Vij A, Fernandez AP. Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease). JAMA Dermatol 2017;153:1015-7.
6. Fawcett JP, Morgan NC, Woods DJ. Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone. Ann Pharmacother 1997;31:1291-5.
7. Song PL, Park YM, Abraham T, Harten B, Zivony A, Neparidze N, et al. Human keratinocytes express functional CD14 and toll-like receptor 4. J Invest Dermatol 2002;119:424-32.
8. Bigliardi PL, Neumann C, Teo YL, Pant A, Bigliardi-Qi M. Activation of the δ-opioid receptor promotes cutaneous wound healing by affecting keratinocyte intercellular adhesion and migration. Br J Pharmacol 2015;172:501-14.
9. Lin TK, Man MQ, Santiago JL, Park K, Roelandt T, Oda Y, et al. Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J Invest Dermatol 2013;133:469-78.
10. Pickett LE, Macdonald J. Injectable diphenhydramine used as anaesthetic for wide local excision with flap closure. J Cutan Med Surg 2017;21:256-7.
11. Gocmen JS, Buyukkokuc U, Caglayan O. In vitro antibacterial activity of some systemic and topical antihistaminic preparations. Clin Investig Med 2009;32:E232.
12. Chen X, Shu S, BayliSS DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci 2009;29:600-9.
13. Kopsky DJ, Keppel Hesselink JM, Bhaskar A, Hariton G, Romanenko V, Casale R. Analgesic effects of topical ketamine. Minerva Anestesiol 2015;81:440-9.
14. Liu FL, Chen TL, Chen RM. Mechanisms of ketamine-induced immunosuppression. Acta Anaesthesiol Taiwan 2012;50:172-7.
15. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: A randomized, double-blind, placebo-controlled trial. Anesthesiology 2005;103:140-6.